Iconovo AB (publ) (STO:ICO)
1.210
-0.010 (-0.82%)
Sep 25, 2026, 2:25 PM CET
Iconovo AB Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.